Stem cells and oxygen therapy may save hips from collapse

NCT ID NCT07560163

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a triple therapy—surgery, stem cells, and hyperbaric oxygen—in 24 patients with early-stage osteonecrosis (bone death) of the hip. After two years, patients reported better hip function and fewer needed a hip replacement. The approach aims to stop the bone from collapsing and avoid major surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
stromal vascular fraction (stem cells)
What this could lead to
If this triple therapy works, it could offer a way to treat early hip bone death without needing a hip replacement.
What could go wrong
This is a small, retrospective study with no comparison group, so results may not apply to everyone. The treatment is complex and not yet proven in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEONECROSIS OF THE FEMORAL HEAD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ankara Bilkent City Hospital

    Ankara, 06800, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.